MCID: PNC013
MIFTS: 48

Pancreatic Ductal Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 12 15
Carcinoma, Pancreatic Ductal 43 71
Malignant Neoplasm of Duct of Wirsung 12
Carcinoma Pancreatic Ductal 54
Pancreatic Duct Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3587
ICD9CM 34 157.3
MeSH 43 D021441
SNOMED-CT 67 187793004
ICD10 32 C25.3
UMLS 71 C0153461 C0887833

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology : 12 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to acinar cell carcinoma and ovarian serous carcinoma. An important gene associated with Pancreatic Ductal Carcinoma is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Innate Immune System and Metabolism of proteins. The drugs Axitinib and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreatic duct, pancreas and liver, and related phenotypes are cellular and cardiovascular system

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 483)
# Related Disease Score Top Affiliating Genes
1 acinar cell carcinoma 30.6 TP53 SMAD4 KRT7
2 ovarian serous carcinoma 30.2 TP53 ERBB2 CDKN2A CDH1
3 retinitis pigmentosa 11 30.2 TP53 MYC EGFR CDKN2A
4 cystadenoma 30.0 MUC6 MUC5AC MUC16 MUC1 KRT7 KRT20
5 papillary adenocarcinoma 29.8 TP53 MUC16 MUC1 KRT7 ERBB2 CDH1
6 adenoma 29.8 TP53 SMAD4 MUC6 MUC5AC MUC1 KRT7
7 tubular adenocarcinoma 29.8 MUC5AC MUC2 MUC1 KRT7 KRT20 ERBB2
8 pancreatic ductal adenocarcinoma 29.5 VEGFA TP53 SMAD4 MYC MUC1 MSLN
9 cystadenocarcinoma 29.5 VEGFA TP53 MUC5AC MUC2 MUC16 MUC1
10 mesothelioma, malignant 29.5 MUC16 MUC1 MSLN KRT7 KRT20 CDKN2A
11 breast ductal carcinoma 29.4 VEGFA TP53 SMAD4 MUC5AC MUC1 KRT7
12 in situ carcinoma 29.2 TP53 MYC MUC1 ERBB2 EGFR EGF
13 mucoepidermoid carcinoma 29.1 TP53 MUC6 MUC5AC MUC2 MUC1 KRT7
14 adenocarcinoma 29.1 VEGFA TYMP TP53 SMAD4 MYC MUC1
15 ovarian serous cystadenocarcinoma 28.4 VEGFA TP53 SMAD4 MYC MUC6 MUC5AC
16 breast cancer 27.9 VEGFA TYMP TP53 SMAD4 MYC MUC1
17 pancreatic adenocarcinoma 27.8 VEGFA TYMP TP53 SMAD4 MYC MUC6
18 gastric cancer 27.8 VEGFA TYMP TP53 SMAD4 MYC MUC6
19 pancreatic cancer 27.5 VEGFA TYMP TP53 TGM2 SMAD4 MYC
20 lung cancer susceptibility 3 27.3 VEGFA TYMP TP53 SMAD4 MYC MUC5AC
21 ovarian cancer 26.6 VEGFA TYMP TP53 TGM2 SMAD4 MYC
22 pancreatic adenosquamous carcinoma 11.4
23 scrotum paget's disease 10.7 MUC1 KRT7
24 anal gland adenocarcinoma 10.6 MUC5AC KRT7
25 intrahepatic biliary papillomatosis 10.6 MUC5AC MUC1
26 colloid carcinoma of the pancreas 10.6 MUC5AC MUC1
27 urethral villous adenoma 10.6 KRT7 KRT20
28 cervical mucinous adenocarcinoma 10.6 MUC6 KRT7
29 cervical basaloid squamous cell carcinoma 10.6 KRT7 CDKN2A
30 nodular hidradenoma 10.6 MUC1 KRT7
31 gastric signet ring cell adenocarcinoma 10.6 KRT7 KRT20
32 nephrogenic adenoma of urinary bladder 10.6 KRT7 KRT20
33 intrahepatic bile duct adenoma 10.6 KRT7 KRT20
34 cap polyposis 10.6 MUC5AC MUC2
35 seminal vesicle adenocarcinoma 10.6 KRT7 KRT20
36 inverted transitional papilloma 10.6 KRT7 CDKN2A
37 anal canal paget's disease 10.6 KRT7 CDKN2A
38 small cell carcinoma of the bladder 10.6 KRT7 KRT20
39 vulva adenocarcinoma 10.6 KRT7 KRT20
40 middle ear adenoma 10.6 MUC1 KRT7
41 cervical adenoid cystic carcinoma 10.6 KRT7 CDKN2A
42 cystitis cystica 10.6 KRT7 KRT20
43 bile duct mucoepidermoid carcinoma 10.6 MUC5AC MUC1 KRT7
44 pancreatic serous cystadenocarcinoma 10.6 KRT7 KRT20
45 vulvar eccrine porocarcinoma 10.6 MUC1 CDKN2A
46 chronic ethmoiditis 10.6 MUC6 MUC5AC MUC1
47 female urethral cancer 10.6 KRT7 KRT20
48 mucinous tubular and spindle renal cell carcinoma 10.6 MUC6 MUC1 KRT7
49 urinary bladder small cell neuroendocrine carcinoma 10.6 KRT7 KRT20
50 vulvar apocrine adenocarcinoma 10.6 KRT7 KRT20

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 CDH1 CDKN2A CXCL12 EGFR ERBB2 KRT7
2 cardiovascular system MP:0005385 10.25 CDH1 CDKN2A CXCL12 EGFR ERBB2 MUC2
3 homeostasis/metabolism MP:0005376 10.25 CDH1 CDKN2A EGFR ERBB2 KRT7 MUC2
4 digestive/alimentary MP:0005381 10.22 CDH1 CDKN2A EGF EGFR ERBB2 MUC2
5 immune system MP:0005387 10.22 CDH1 CDKN2A CXCL12 EGF EGFR MUC2
6 endocrine/exocrine gland MP:0005379 10.2 CDH1 CDKN2A EGF EGFR ERBB2 MUC2
7 integument MP:0010771 10.02 CDH1 CDKN2A EGF EGFR ERBB2 MYC
8 neoplasm MP:0002006 9.96 CDH1 CDKN2A EGFR ERBB2 MUC2 MYC
9 muscle MP:0005369 9.92 CDKN2A CXCL12 EGFR ERBB2 MYC SMAD4
10 no phenotypic analysis MP:0003012 9.76 CDH1 CDKN2A CXCL12 EGFR MYC TGM2
11 normal MP:0002873 9.65 CDH1 CXCL12 EGF EGFR ERBB2 MSLN
12 reproductive system MP:0005389 9.32 CDH1 CDKN2A CXCL12 EGF EGFR ERBB2

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
5 Protein Kinase Inhibitors Phase 3
6 Immunologic Factors Phase 3
7 Anti-Infective Agents Phase 3
8 Albumin-Bound Paclitaxel Phase 3
9 Tubulin Modulators Phase 3
10 Immunosuppressive Agents Phase 3
11 Antiviral Agents Phase 3
12 Antimetabolites Phase 3
13 Antimitotic Agents Phase 3
14
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
15
Enoxaparin Approved Phase 2 9005-49-6 772
16
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
18
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
19
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
20
Floxuridine Approved Phase 2 50-91-9 5790
21
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
22
Apaziquone Investigational Phase 1, Phase 2 114560-48-4 5813717
23
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
24 Antineoplastic Agents, Immunological Phase 2
25 Gastrointestinal Agents Phase 2
26 Hormones Phase 2
27 Fibrinolytic Agents Phase 2
28 Antineoplastic Agents, Hormonal Phase 2
29 Antiemetics Phase 2
30 Hormone Antagonists Phase 2
31 glucocorticoids Phase 2
32 Anticoagulants Phase 2
33 Anti-Inflammatory Agents Phase 2
34
Liposomal doxorubicin Phase 2 31703
35 Pharmaceutical Solutions Phase 2
36 Liver Extracts Phase 2
37
Carboplatin Approved Phase 1 41575-94-4 10339178 38904 498142
38
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
39
Etoposide Approved Phase 1 33419-42-0 36462
40
Durvalumab Approved, Investigational Phase 1 1428935-60-7
41
Pancrelipase Approved, Investigational Phase 1 53608-75-6
42
leucovorin Approved Phase 1 58-05-9 6006 143
43
Fluorouracil Approved Phase 1 51-21-8 3385
44
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 43805 6857599 5310940 9887054
45
Levoleucovorin Approved, Investigational Phase 1 68538-85-2
46
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
47
Pembrolizumab Approved Phase 1 1374853-91-4
48
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
49
Tremelimumab Investigational Phase 1 745013-59-6
50 Hematinics Phase 1

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer. Completed NCT00471146 Phase 3 AG-013736;Gemcitabine;Gemcitabine;placebo
2 A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma Recruiting NCT03899636 Phase 3 Modified FOLFIRINOX Regimen
3 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
5 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Unknown status NCT02529579 Phase 1, Phase 2 Gemcitabine
6 A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer Unknown status NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
7 Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2 Targeted Therapy Tailored Treatment;Standard Chemotherapy
8 A Multicenter Phase II Trial of Weekly Gemcitabine, Paclitaxel, and Hyperfractionated External Irradiation (63.80 GY) for Locally Advanced Pancreatic Cancer Completed NCT00226746 Phase 2 Paclitaxel and gemcitabine
9 A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer Completed NCT02653313 Phase 1, Phase 2 Parvovirus H-1 (H-1PV)
10 A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
11 A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
12 An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
13 A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20;Nab-paclitaxel;Gemcitabine;Dexamethasone;Enoxaparin
14 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
15 Panitumumab in Combination With Cisplatin/Gemcitabine Chemotherapy in Patients With Cholangiocarcinomas - a Randomized Clinical Phase II Study Completed NCT01320254 Phase 2 Cisplatin, Gemcitabine, Panitumumab;Cisplatin, Gemcitabine
16 Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma - A Randomized Controlled Trial Recruiting NCT04146441 Phase 2 Chemotherapy
17 A Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases Recruiting NCT03856658 Phase 2 Floxuridine (FUDR);Heparinized Saline
18 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Terminated NCT02243007 Phase 2 FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
19 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Completed NCT01478685 Phase 1 CC-486;Carboplatin;ABI-007
20 A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. Completed NCT02658214 Phase 1 paclitaxel + carboplatin;carboplatin + etoposide;gemcitabine + carboplatin;nab-paclitaxel (paclitaxel-albumin) + carboplatin;oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);nab-paclitaxel (paclitaxel-albumin) + gemcitabine;cisplatin + 5-fluorouracil (5FU)
21 A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed NCT02259114 Phase 1 MK-8628
22 A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Recruiting NCT04045496 Phase 1 JAB-3312
23 A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
24 A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors Active, not recruiting NCT02646748 Phase 1 Pembrolizumab;itacitinib;INCB050465
25 A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Not yet recruiting NCT04121286 Phase 1 JAB-3312
26 To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells Unknown status NCT02451384
27 Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study Unknown status NCT03500068
28 A Clinical Validation Study on the Efficacy of MicroRNA-25 Level Detection in Assisting the Diagnosis of Pancreatic Cancer Unknown status NCT03432624
29 An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy Unknown status NCT02310230
30 Evaluation of Safety and Feasibility of Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) for Solid Pancreatic Neoplasms Unknown status NCT03435770
31 CT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility Study Completed NCT00588367
32 Continuous Monitoring of Vital Signs in Hospitalized Patients Completed NCT02933307
33 Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence Completed NCT02150746
34 Prospective Populationbased Study on Pancreatic Cancer in Stockholm- Mutation Profiling Characteristics, Biobanking and Risk Factors. Completed NCT02162823
35 Endoscopic Retrograde CholangioPancreatography Endomicroscopy Registry Outcomes Database Completed NCT00779688
36 Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study Recruiting NCT02750657
37 Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas Recruiting NCT02817308
38 Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma Recruiting NCT03899649 SOC
39 Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1): a Multicenter Stepped-wedge Cluster Randomized Controlled Trial Recruiting NCT03513705
40 Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy Recruiting NCT02928081
41 Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial Recruiting NCT03257150
42 A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers Terminated NCT01413451 Early Phase 1 Amatuximab (MORab-009)
43 Role of Adrenomedullin in Early Diagnosis of Pancreatic Cancer in New Onset Diabetes Patients Terminated NCT02456051

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


gemcitabine
Gemcitabine hydrochloride

Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

19
Pancreatic Duct

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

40
Pancreas, Liver, Lung, Prostate, Lymph Node, T Cells, Endothelial

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 345)
# Title Authors PMID Year
1
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. 61 54
16951195 2006
2
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? 54 61
16018800 2005
3
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. 61 54
15725805 2005
4
The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. 54 61
15084978 2004
5
MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. 61 54
14681945 2003
6
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. 61 54
12717266 2003
7
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. 54 61
11787853 2001
8
Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. 54 61
11391801 2001
9
Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. 61 54
11431719 2001
10
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives. 54 61
11391857 2001
11
Three cases of follicular pancreatitis: association between radiological findings and pathological features. 61
32577208 2020
12
Fibrosis and cancer: A strained relationship. 61
32147542 2020
13
Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma. 61
31786688 2020
14
Primary non-ampullary duodenal follicular lymphoma presenting with obstructive jaundice. 61
31401784 2020
15
NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. 61
31940589 2020
16
EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation in vitro. 61
32161011 2020
17
Solitary pancreatic metastasis of gastric cancer with synchronous pancreatic ductal carcinoma: A case report. 61
32416485 2020
18
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer. 61
31527373 2020
19
PACAP and PAC1 receptor expression in pancreatic ductal carcinoma. 61
31788045 2019
20
MCLA-128 Fights NRG1 Fusion-Positive Cancers. 61
31685488 2019
21
Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma. 61
31743881 2019
22
Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. 61
31665640 2019
23
Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer. 61
31404021 2019
24
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. 61
31164413 2019
25
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. 61
31533831 2019
26
Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. 61
31148345 2019
27
ILF2 promotes anchorage independence through direct regulation of PTEN. 61
31423236 2019
28
MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex. 61
31242384 2019
29
Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model. 61
31404387 2019
30
[MicroRNA-21 correlates TGF-β1 pathway of pancreatic ductal adenocarcinoma]. 61
31413212 2019
31
Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer. 61
31177164 2019
32
Mixed ductal-acinar cell carcinoma of the pancreas: A case report. 61
30967946 2019
33
Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma. 61
30776178 2019
34
[A Case Report of Conversion Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastasis after Chemotherapy]. 61
31164541 2019
35
Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells. 61
30898113 2019
36
Diabetes of the exocrine pancreas. 61
30151918 2019
37
Invasive Ductal Carcinoma Arising in Mucinous Cystic Neoplasm of Pancreas: A Case Report. 61
30798329 2019
38
Prognostic Value of MicroRNA-15a in Human Cancers: A Meta-Analysis and Bioinformatics. 61
31061821 2019
39
Newer Trends in Pancreatic Cancer Treatment: Genetic Alterations and the Role of Immune Therapeutic and Targeted Therapies. 61
31679211 2019
40
Clinical impact of margin status on survival and recurrence pattern after curative-intent surgery for pancreatic cancer. 61
29249392 2019
41
Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. 61
31048929 2019
42
Cytogenetic, Molecular, and Translational Applications in Pancreatic Ductal Adenocarcinoma: Current Evidence and Future Concepts. 61
31679207 2019
43
SMAD4 and TGFβR2 expression in pancreatic ductal carcinoma. 61
31912090 2019
44
A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy. 61
31887205 2019
45
An Autopsy Case of Anaplastic Pancreatic Ductal Carcinoma (Spindle Cell Type) Multiple Onset in the Pancreas. 61
31123460 2019
46
Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis. 61
30336280 2018
47
Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy. 61
30223034 2018
48
Anaplastic pancreatic cancer diagnosed with endoscopic ultrasound guided fine needle aspiration showing hypervascular tumor: A case report. 61
30544436 2018
49
Small pancreatic ductal carcinomas on triple-phase contrast-enhanced computed tomography: enhanced rims and the pathologic correlation. 61
29796845 2018
50
Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure. 61
30515264 2018

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 VEGFA TP53 MYC MUC6 MUC5AC MUC2
2
Show member pathways
13.84 TP53 SMAD4 MYC MUC6 MUC5AC MUC2
3
Show member pathways
13.76 VEGFA TYMP TP53 SMAD4 MYC MUC1
4
Show member pathways
13.72 VEGFA TYMP TP53 SMAD4 MYC ERBB2
5
Show member pathways
13.69 SMAD4 MYC MUC6 MUC5AC MUC2 MUC16
6
Show member pathways
13.53 VEGFA TYMP TP53 SMAD4 MYC ERBB2
7
Show member pathways
13.39 VEGFA TP53 MYC MUC1 ERBB2 EGFR
8
Show member pathways
13.34 TYMP SMAD4 ERBB2 EGFR EGF CXCL12
9
Show member pathways
13.32 VEGFA TYMP ERBB2 EGFR EGF CXCL12
10
Show member pathways
13.11 TYMP TP53 TGM2 EGFR EGF CXCL12
11
Show member pathways
13.03 VEGFA TP53 MYC ERBB2 EGFR EGF
12
Show member pathways
12.98 VEGFA TP53 MYC EGFR CXCL12 CDKN2A
13 12.8 VEGFA TP53 MYC ERBB2 EGFR EGF
14
Show member pathways
12.77 VEGFA TP53 SMAD4 MYC ERBB2 EGFR
15
Show member pathways
12.7 TP53 ERBB2 EGFR EGF CDKN2A CDH1
16
Show member pathways
12.63 VEGFA TP53 MYC ERBB2 EGFR EGF
17 12.54 VEGFA TP53 MYC ERBB2 EGFR CDKN2A
18
Show member pathways
12.48 TP53 SMAD4 MYC MUC2 ERBB2 EGFR
19
Show member pathways
12.47 MUC6 MUC5AC MUC2 MUC16 MUC1
20
Show member pathways
12.43 TYMP ERBB2 EGFR EGF CXCL12 CDH1
21 12.4 TP53 SMAD4 MYC CDKN2A CDH1
22 12.38 TP53 SMAD4 MYC CDKN2A
23 12.38 VEGFA TP53 SMAD4 MYC ERBB2 EGFR
24
Show member pathways
12.35 TP53 ERBB2 EGFR EGF
25 12.34 VEGFA TP53 MYC ERBB2 EGFR
26
Show member pathways
12.32 VEGFA TP53 SMAD4 MYC MUC1 EGFR
27
Show member pathways
12.31 TYMP TP53 MYC EGFR CXCL12
28
Show member pathways
12.27 MUC6 MUC5AC MUC2 MUC16 MUC1
29
Show member pathways
12.26 MYC MUC1 ERBB2 EGFR EGF CDH1
30
Show member pathways
12.18 MYC ERBB2 EGFR EGF
31
Show member pathways
12.13 MUC6 MUC5AC MUC2 MUC16 MUC1
32 12.08 VEGFA TP53 SMAD4 MYC EGFR EGF
33 12.07 VEGFA TP53 SMAD4 MYC EGFR CDH1
34 12.03 VEGFA TP53 MYC MUC1
35 12.01 VEGFA ERBB2 EGFR EGF
36
Show member pathways
12 ERBB2 EGFR EGF CXCL12
37 11.98 TP53 SMAD4 MYC ERBB2 CDKN2A
38 11.94 TP53 MYC EGFR EGF CDKN2A
39
Show member pathways
11.92 VEGFA MYC ERBB2 EGFR
40
Show member pathways
11.91 MUC6 MUC5AC MUC2 MUC16 MUC1
41 11.83 TP53 SMAD4 MYC
42 11.78 TP53 ERBB2 CDKN2A
43 11.77 TYMP ERBB2 EGFR EGF CXCL12
44 11.77 SMAD4 ERBB2 EGFR CDH1
45 11.76 TP53 MYC ERBB2 EGFR
46 11.75 VEGFA TP53 SMAD4 CDKN2A
47 11.74 MYC ERBB2 EGFR
48 11.73 MYC EGFR EGF
49 11.73 TP53 MYC ERBB2
50 11.72 VEGFA SMAD4 CXCL12

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 VEGFA MUC6 MUC5AC MUC16 MUC1 MSLN
2 Golgi lumen GO:0005796 9.02 MUC6 MUC5AC MUC2 MUC16 MUC1
3 mucus layer GO:0070701 8.96 MUC5AC MUC2

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.09 VEGFA TP53 SMAD4 MYC ERBB2 EGFR
2 positive regulation of cell proliferation GO:0008284 9.97 VEGFA MYC ERBB2 EGFR EGF CXCL12
3 positive regulation of transcription, DNA-templated GO:0045893 9.95 TP53 SMAD4 MYC EGFR EGF CDKN2A
4 positive regulation of cell migration GO:0030335 9.91 VEGFA EGFR EGF CXCL12
5 positive regulation of gene expression GO:0010628 9.91 VEGFA TP53 MYC ERBB2 EGF CDKN2A
6 in utero embryonic development GO:0001701 9.89 VEGFA TP53 SMAD4 MYC
7 cellular response to drug GO:0035690 9.76 TP53 MYC EGFR
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 TGM2 MYC EGFR
9 cellular response to epidermal growth factor stimulus GO:0071364 9.7 MYC ERBB2 EGFR
10 ovarian follicle development GO:0001541 9.69 VEGFA SMAD4 MYC
11 positive regulation of epithelial cell proliferation GO:0050679 9.67 VEGFA MYC ERBB2 EGFR
12 regulation of cell motility GO:2000145 9.65 ERBB2 EGFR EGF
13 ERBB2 signaling pathway GO:0038128 9.63 ERBB2 EGFR EGF
14 positive regulation of MAP kinase activity GO:0043406 9.62 VEGFA ERBB2 EGFR EGF
15 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.6 TP53 EGFR
16 positive regulation of axon extension involved in axon guidance GO:0048842 9.57 VEGFA CXCL12
17 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.56 TP53 MUC1
18 positive regulation of cell adhesion GO:0045785 9.56 VEGFA TGM2 ERBB2 CXCL12
19 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.55 VEGFA TP53
20 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.55 MUC6 MUC5AC MUC2 MUC16 MUC1
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.54 ERBB2 CDKN2A
22 negative regulation of ERBB signaling pathway GO:1901185 9.13 ERBB2 EGFR EGF
23 O-glycan processing GO:0016266 9.02 MUC6 MUC5AC MUC2 MUC16 MUC1

Molecular functions related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 VEGFA TP53 TGM2 SMAD4 MYC MUC6
2 growth factor activity GO:0008083 9.26 VEGFA TYMP EGF CXCL12

Sources for Pancreatic Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....